Sumant Kulkarni

Tazeen Ahmad

Ami Fadia

Charles Duncan

Joel Beatty

Marc Goodman

Ritu Baral

Tessa Romero

Ashwani Verma

David Hoang

Gregory Renza

Jason Butler

Malcolm Hoffman

Yatin Suneja

Basma Radwan Ibrahim

Brian Abrahams

Chi Wen Chin

Danielle Brill

Greg Rirenza

Jay Olson

Jeff Hung

Julian Hung

Julian Pino

Keith Tapper

Michael Riad

Paul Matteis

Paul Mattis

Salveen Richter

Sean Laaman

Tess Romero

- Acadia Pharmaceuticals anticipates top-line Phase 3 COMPASS data for **ACP-101** (carbetocin) in Prader-Willi syndrome in **early Q4**.  **[1070494_2147447_1]**  The study is designed with **170 patients** comparing a **3.2 mg dose** to placebo, building on prior trial data where this dose showed statistical significance (p-value **0.016**) on the HQ-CT endpoint.  **[1070494_2147447_2]** **[1070494_2147447_3]** 
- For **ACP-204**, Phase 2 data for Alzheimer's disease psychosis (ADP) is anticipated in **mid-2026**.  **[1070494_2147447_4]**  A new study for Lewy body dementia psychosis (LBDP) will enroll **180 patients**.  **[1070494_2147447_5]** 
- A Phase 2 study for **ACP-211**, a noradrenaline compound for Major Depressive Disorder (MDD), is set to begin in **Q4 2025**, enrolling **150 patients** with a primary endpoint at **week 4**.  **[1070494_2147447_6]** **[1070494_2147447_7]** 
- Other pipeline catalysts include the initiation of a Phase 1 study for **ACP-271** (targeted dyskinesia and Huntington’s disease) by the **end of 2025** and the start of a triphenotide trial in Japan.  **[1070494_2147447_7]**

Acadia Pharmaceuticals Provides Pipeline Updates on Key Programs and Upcoming Catalysts

ACADIA PHARMACEUTICALS (ACAD)